Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer.
IGF1 receptor
ZYG11A
endometrial cancer
insulin-like growth factor-1 (IGF1)
p53
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
09 Jul 2019
09 Jul 2019
Historique:
received:
16
05
2019
accepted:
19
06
2019
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
20
7
2019
Statut:
epublish
Résumé
The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (
Identifiants
pubmed: 31320996
doi: 10.18632/oncotarget.27055
pii: 27055
pmc: PMC6633887
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4437-4448Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare that they have no competing interests.
Références
Mol Hum Reprod. 2001 Dec;7(12):1115-22
pubmed: 11719588
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Clin Cancer Res. 2002 May;8(5):1271-9
pubmed: 12006548
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8247-52
pubmed: 12821780
Int J Cancer. 2003 Dec 20;107(6):873-7
pubmed: 14601044
J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44
pubmed: 15001582
Lancet. 2004 Apr 24;363(9418):1346-53
pubmed: 15110491
Pediatr Endocrinol Rev. 2005 Sep;3(1):11-9
pubmed: 16369209
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Trends Endocrinol Metab. 2006 Aug;17(6):236-42
pubmed: 16815029
EMBO Rep. 2007 Mar;8(3):279-86
pubmed: 17304241
Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):302-10
pubmed: 17315038
Obesity (Silver Spring). 2008 Jul;16(7):1636-50
pubmed: 18421271
Trends Endocrinol Metab. 2008 Aug;19(6):197-205
pubmed: 18515143
Arch Physiol Biochem. 2009 May;115(2):58-71
pubmed: 19485702
Nat Rev Endocrinol. 2011 Jan;7(1):11-24
pubmed: 20956999
Eur J Endocrinol. 2011 Apr;164(4):485-9
pubmed: 21292919
Gynecol Oncol. 2011 May 1;121(2):383-9
pubmed: 21295335
Sci Transl Med. 2011 Feb 16;3(70):70ra13
pubmed: 21325617
Endocr Relat Cancer. 2011 Jul 04;18(4):R125-47
pubmed: 21606157
Oncogene. 2012 May 31;31(22):2703-14
pubmed: 21963847
Eur J Cancer. 2012 Jul;48(10):1570-80
pubmed: 22033326
Nat Rev Cancer. 2012 Feb 16;12(3):159-69
pubmed: 22337149
Expert Opin Ther Targets. 2013 Mar;17(3):307-20
pubmed: 23294364
J Bone Miner Res. 2013 Jul;28(7):1575-86
pubmed: 23456957
Cell Mol Life Sci. 2014 Jul;71(13):2403-27
pubmed: 24276851
Growth Horm IGF Res. 2014 Aug;24(4):112-8
pubmed: 24863809
Front Endocrinol (Lausanne). 2014 May 19;5:76
pubmed: 24904527
Front Endocrinol (Lausanne). 2015 Jul 03;6:106
pubmed: 26191041
Oncotarget. 2016 Feb 16;7(7):8029-42
pubmed: 26771237
Endocr Relat Cancer. 2016 May;23(5):399-410
pubmed: 27090428
Front Oncol. 2016 Jun 23;6:159
pubmed: 27446805
N Engl J Med. 1989 Oct 12;321(15):989-95
pubmed: 2779634
J Cell Biol. 2016 Oct 24;215(2):151-166
pubmed: 27810909
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1045-1050
pubmed: 29339473
Int J Cancer. 2018 Nov 2;:null
pubmed: 30387875
Isr J Med Sci. 1966 Mar-Apr;2(2):152-5
pubmed: 5916640
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Regul Pept. 1993 Oct 20;48(1-2):165-77
pubmed: 7505463
Genomics. 1995 Mar 1;26(1):151-8
pubmed: 7782076
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8318-23
pubmed: 8710868
Am J Pathol. 1997 Jan;150(1):177-85
pubmed: 9006334
Science. 1998 Jan 23;279(5350):563-6
pubmed: 9438850
Lancet. 1998 May 9;351(9113):1393-6
pubmed: 9593409